Researchers cautioned that study results involving laboratory mouse models do not always translate into clinical treatment of human patients
Researchers used blood platelets and bone marrow cells to deliver potentially curative
to mouse models of the human genetic disorder Hurler syndrome – an often fatal condition that causes organ damage and other medical complications.
Scientists from Cincinnati Children’s Hospital Medical Center and the National Institute of Neurological Disorders and Stroke (NINDS) report their unique strategy for treating the disease the week of Feb. 3-7 in Proceedings of the National Academy of Sciences (PNAS).
Researchers were able to genetically insert into the cells a gene that produces a critical lysosomal enzyme (called IDUA) and then inject the engineered cells into mice to treat the disorder. Follow up tests showed the treatment resulted in a complete metabolic correction of the disease, according to the authors.
“Our findings demonstrate a unique and somewhat surprising delivery pathway for lysosomal enzymes,” said Dao Pan, PhD, corresponding author and researcher in the Division of Experimental Hematology and Cancer Biology at Cincinnati Children’s. “We show proof of concept that platelets and megakaryocytes are capable of generating and storing fully functional lysosomal enzymes, which can lead to their targeted and efficient delivery to vital tissues where they are needed.”
The mice tested in the study modeled human Hurler syndrome, a subset of disease known as mucopolysaccharidosis type I (MPS I), one of the most common types of lysosomal storage diseases. MPS I is a lysosomal storage disease in which people do not make an enzyme called lysosomal alpha-L-iduronidase (IDUA).
IDUA helps break down sugar molecules found throughout the body, often in mucus and fluids around joints, according to the National Library of Medicine/National Institutes of Health. Without IDUA, sugar molecules build up and cause organ damage. Depending on severity, the syndrome can also cause deafness, abnormal bone growth, heart valve problems, joint disease, intellectual disabilities and death.
Enzyme replacement therapy can be used to treat the disease, but it is only temporary and not curative. Bone marrow transplant using hematopoietic stem cells also has been tested on some patients with mixed results. The transplant procedure can carry severe risks and does not always work.
Pan and her colleagues – including Roscoe O. Brady, MD, a researcher at NINDS – report that using platelets and megakaryocytes for gene therapy is effective and could reduce the risk of activating cancer-causing oncogenes in hematopoietic stem cells.
The authors said tests showed that human megakaryocytic cells were capable of overexpressing IDUA, revealing their capacity for potential therapeutic benefit. While engineering megakaryocytes and platelets for infusion into their mouse models of Hurler, the scientists report they were able to release IDUA directly into amply sized extracellular spaces or inside micro-particles as the cells matured or activated. The cells were able to produce and package large amounts of functional IDUA and retained the capacity to cross-correct patient cells.
After infusing mouse models of Hurler with the genetically modified cells, researchers said this led to long-term normalization of IDUA levels in the animal’s blood with versatile delivery routes and on-target preferential distribution to the liver and spleen. The treatment led to a complete metabolic correction of MPS I in most peripheral organs of the mice.
Researchers cautioned that study results involving laboratory mouse models do not always translate into clinical treatment of human patients, and that additional research is needed for this prospective therapy.
The Latest on: Hurler syndrome
via Google News
The Latest on: Hurler syndrome
- Cord blood protects baby’s brain from Hurler syndromeon November 19, 2019 at 4:00 pm
Experts say the findings emphasize the need for early diagnosis of the condition, called Hurler syndrome, preferably through newborn screening programs. [related] Hurler syndrome is the most ...
- Post-transplant laronidase augmentation for children with Hurler syndrome: biochemical outcomeson October 1, 2019 at 2:11 am
Allogeneic hematopoietic cell transplantation (HCT) benefits children with Hurler syndrome (MPS-IH). However, survivors remain burdened by substantial MPS-IH related residual disease. We studied ...
- Magenta Therapeutics Presents Updated Phase 2 Clinical Data on MGTA-456 Cell Therapy at American Academy of Neurology Annual Meetingon May 8, 2019 at 5:00 pm
The Company plans to enroll 12 patients in the ongoing Phase 2 study in inherited metabolic disorders, which include cALD, Hurler syndrome, metachromatic leukodystrophy and globoid cell leukodystrophy ...
- Mucopolysaccharidosis Treatment Market Details 2017 – 2027: Future Demands, Dynamicson March 13, 2019 at 7:48 am
The mucopolysaccharidosis (MPS) is classified as Hurler syndrome (MPS IH), Hurler-Scheie syndrome (MPS I-H/S), Sanfilippo syndrome (MPS III), Scheie syndrome (MPS IS), Hunter syndrome (MPS II), ...
- Why Sangamo Therapeutics Lost 22.9% of Its Value in Februaryon March 4, 2019 at 5:07 am
After the company reported interim results from an early-stage study evaluating its zinc-finger nuclease gene-editing approach in Hurler syndrome, shares of Sangamo Therapeutics (NASDAQ ...
- Rare disease sufferers call for earlier genetic testing, better training for GPs to avoid years of misdiagnosison March 2, 2019 at 4:33 am
The 17-year-old was diagnosed with the rare genetic disease mucopolysaccharidosis (MPS1) — also known as Hurler Syndrome — just before she turned two, after suffering hydrocephalus or fluid on ...
- Mucopolysaccharidosis Type I (Hurler Syndrome) R&D Pipeline Analysis Report, H2-2018on January 28, 2019 at 8:24 am
Dublin, Jan. 28, 2019 (GLOBE NEWSWIRE) -- The "Mucopolysaccharidosis Type I (Hurler Syndrome) R&D Pipeline Analysis Report, H2-2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
- Magenta stem cell transplant drug seems to work, but is it safe?on November 1, 2018 at 8:16 am
Magenta’s stem cell therapy MGTA-456 met efficacy targets in the first few patients enrolled in a phase 2 trial to be presented at ASH next month, but with a question about safety. MGTA-456 is an ...
- Hurler Syndrome | A Pipeline Analysis Report 2018 | Technavioon July 6, 2018 at 6:40 am
Technavio has announced its pipeline analysis report on the Hurler syndrome market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data ...
- Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparisonon March 8, 2018 at 7:54 am
Ethics precludes randomized comparison of ERT with HCT, but insight into this comparison is presented with an international cohort of patients with Hurler syndrome who received long-term ERT from ...
via Bing News